21 September 2021

The main purpose of SUNRISE-CRC is to determine whether treatment with a high dose of sunitinib provides a better chance of survival and slows the progression of (colo)rectal cancer (CRC) more than standard treatment with TAS-102. Sunitinib, at a low daily dose, has been approved as a treatment for kidney cancer, but not yet for colorectal and rectal cancer. The standard treatment for metastatic colorectal or rectal cancer in this line is TAS-102, a form of chemotherapy. This study also examines whether certain proteins or other characteristics can be detected in the patient's blood and tumor that are predictive of the effect of the treatment. The biomaterial and associated clinical data are being collected and stored in the SUNRISE-CRC biobank.

  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud biobank

Related news items


Farewell Dorine Swinkels

1 September 2026

On Friday, September 4th, 2026, Dorine Swinkels will retire as Professor of Experimental Clinical Chemistry at Radboudumc. She is also leaving the Radboud Biobank.

go to page

Greening Radboud Biobank – reduction number of aliquots in storage for future initiatives

1 September 2026

Like LUMC and NKI, the Radboud Biobank will also store fewer aliquots per collection tube.

go to page

Effect of Fit & Funding on external invoices

1 September 2026

The Radboud Biobank not only manages issuances and projects for Radboudumc but also provides external services. The Radboud Biobank invoices the external organization for these services.

go to page

New link between iLES and Castor EDC connects clinical data and biobank material

1 September 2026

The Biobank Information Management System, iLES, is now linked to Castor EDC. This development was realized within a KWF-funded project.

go to page

Radboud Biobank's 2025 annual report

3 March 2026

The Radboud Biobank's 2025 annual report is now available on request.

go to page

Aevai Health developed a virtual assistant

3 March 2026

Aevai Health has developed Alva - a virtual assistant to engage research participants, which can support participants with health literacy, understanding research protocols, and with using measurement devices.

go to page